These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27872331)

  • 1. Systemic hypersensitivity to fosaprepitant - A report of two cases.
    Baxley A; Lee Z; Medina P
    J Oncol Pharm Pract; 2018 Jan; 24(1):76-78. PubMed ID: 27872331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
    Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
    J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
    Boccia R; Geller RB; Clendeninn N; Ottoboni T
    Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
    Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions.
    Gonçalves SC; Sanches SM; Bueno CT; Villela de Castro DL; Damascena A; Santos GRC
    J Infus Nurs; 2017; 40(6):380-383. PubMed ID: 29112587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
    Pritchett W; Kinsley K
    Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
    Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
    Sun S; Schaller J; Placek J; Duersch B
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):509-13. PubMed ID: 23860958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
    Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
    Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy.
    Segna AN; Baron RH; Cohen B
    Clin J Oncol Nurs; 2020 Dec; 24(6):E79-E84. PubMed ID: 33216065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
    Kameda K; Kiba T; Ogawa Y; Kimoto S; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1255-7. PubMed ID: 25335710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
    Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
    Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.